STOCKS TELEGRAPH

Tag: QLGN

  • Qualigen Therapeutics, Inc. (QLGN) Stock on the Rise Following IND Submission for Novel Covid-19 Treatment, QN-165

    Qualigen Therapeutics, Inc. (QLGN) stock prices were up 1.6854% as of the market opening on July 14th, 2021, with premarket trading having seen the stock rise sharply. As of writing, the price per share of QLGN stock was USD$1.81.

    IND Submission

    July 14th, 2021 saw the biotechnology company announce the submission of an Investigational New Drug Application to the U.S Food and Drug Administration with an initial target indication for the treatment of hospitalized Covid-19 patients with the company’s QN-165. The DNA aptamer is a broad-based antiviral drug candidate that has shown antiviral activity in various in vitro assays against a plethora of viruses.

    Milestone for QLGN

    The significant milestone is the first IND application submitted by the company for its most advanced therapeutics program. The IND application submission for Phase 1b/2a clinical trials for QN-165 represents another step in the company’s evolution from a globally patented and commercially successful diagnostics company to a clinical-stage therapeutics company with multiple programs.

    QN-165

    QN-165 is a unique drug candidate that presents an entirely novel approach to combating viruses, which the company thinks it will be able to work against all virus strains and variants. The treatment is a piece of synthetic DNA that does not target the coronavirus directly, as existing treatments do. Rather, it targets and binds to the nucleolin protein and has the capacity to enter cells that overexpress nucleolin. Nucleolin is exploited by viruses such as Covid-19 to gain access to a cell, manipulating it for its own viral replication purposes.

    Scope of QN-165

    By tying up nucleolin, QN-165 is anticipated to block the mechanism entirely, thus preventing the virus replication process. Because of this, even the mutation of the virus is not expected to result in a loss of efficacy of the treatment, on account of nucleolin being targeted instead of the virus itself. This is what the company believes will make the treatment effective against a plethora of viral mutations, including all strains and variants of the novel coronavirus.

    Future Outlook for QLGN

    With the world hurtling towards global immunizations, the onslaught of variants and strains that pop up across the globe are becoming an increasingly significant concern. Treatments such as QN-165 are set to address those concerns, thereby signaling the massive potential for commercialization and proliferation of the expansive market. Investors are hopeful that management will leverage its resources to deliver the treatment as quickly as possible, thus ensuring maximum increases in shareholder value.

  • Qualigen Therapeutics, Inc. (QLGN) fell in the after-hours trading session; here’s why

    Qualigen Therapeutics, Inc. (QLGN) fell in the after-hours trading session; here’s why

    QLGN stock had plunged -18.08% to trade at $2.13 in the after-market at the time of writing. QLGN stock closed the Friday trading session at $2.60 which was 0.76% lower. The volume of trade was 0.48 million shares which was lower than the average daily volume of 1.49 million for the past 50 days.

    What is recent activity of QLGN stock

    The biotech company has been operationally active in the month of March through engaging in conferences, making administrative changes and advances, as well as the acquisition of new biotech technologies.

    On March 9th, the QLGN stock announced that it has a newly gained Chief Financial Officer for Qualigen’s corporate headquarters in Carlsbad, California. The company promoted ShishirSinha to CFO who has been valuable to the company for the past 15 years.

    The company also took part in the presentation at the Oppenheimer 31st Annual Healthcare Conference from 16-18th March. The conference would provide investors a broad spectrum of all the public and private healthcare companies in the health industries of various specialties and niches.

    On 1st March, QLGN announced that it was looking into an entered agreement known as Material Evaluation and Option Agreement with the University College of London. The agreement purpose is to seek options of advancing the commercial expansion of drug candidate ALAN AS1411-GNP. The agreement is known as Material Evaluation and Option Agreement.

    Core operational focus of QLGN stock

    Currently, Qualigen Therapeutics is focusing on maintaining and expanding its core FastPack® system that has been approved by the Food and Drug Administration. The system is also ISO-certified and sold across the globe through a commercial partnership with Sekisui Diagnostics, LLC. FastPack® system has helped physicians, medical clinics, and hospitals in providing efficiency in diagnostic procedures. The system comes in the form of diagnostic instruments and test kits. The FastPack System specifically focuses on rapid point-of-care diagnostic tests for cancer, as well as men’s health, hormone functions, and vitamin D status. Since the pandemic has struck, FastPack® also provides quick and efficient diagnostics of anti –bodies against SARS-CoV-2.

    Background into the Company

    Qualigen therapeutics is a biotechnology company based in Carlsbad, California. It aims to focus on the design and production of new therapies that are novel treatment, innovative in nature.  These treatments are specifically being clinically experimented and bio-engineered to focus on cancer and infectious diseases.

    The Qualigen Therapeutic has cancer therapeutics as candidates that are still going through the development stage. The pipeline of QLGN stock includes three candidates which are ALAN (AS1411-GNP), RAS-F and STARSTM.

    ALAN (AS1411-GNP) is a cancer drug candidate that has its DNA coated in gold nanoparticles. The uniqueness of this drug is that in can target numerous cancer types and does it with minimal side effects. The base of the drug is the nucleolin-targeting DNA aptamer. The foundational DNA aptamer is also an experimental candidate that is used for the treatment of viral-based infections as well as COVID-19.

    STARS is also a DNA/RNA based treatment which a device that is also in the candidate stage. The purpose of this device is to remove the targeted tumor and viral compounds in the blood circulation.

    RAS-F belongs to the family of RAS oncongene protein-protein interaction inhibitor small molecules. This family of RAS molecules is used for the prevention of mutated RAS genes’ proteins from binding in their effector proteins. Prevention of this binding allows for the stoppage of tumor growth process. This is effective especially in the lung cancer, pancreatic and colorectal cancers.

  • 32 Stocks Making Sharp Moves in Pre Market Session

    32 Stocks Making Sharp Moves in Pre Market Session

    Sundial Growers Inc. (SNDL) stock soared 1.72% to $0.5088 in the pre-market trading after declaring $50 million prepayment on senior secured non-revolving term credit facility. The most recent rating by CIBC, on August 17, 2020, is a Neutral.

    FuelCell Energy Inc. (FCEL) is up more than 2.09% at $8.31 in pre-market hours Wednesday December 16, 2020. The stock had jumped over 5.71% to $8.14 in the last trading session.

    BioCardia Inc. (NASDAQ: BCDA) shares are trading up 5.22% at $7.05 at the time of writing after reporting that it has entered into definitive agreements with investors for the purchase and sale of 1,789,474 shares of its common stock at a purchase price of $4.75 per share Company’s 52-week ranged between $1.91 to $6.95.

    Before the trading started on December 16, 2020, MicroVision Inc. (MVIS) is down -1.9% to reach $4.13. It has been trading in a 52-week range of $0.15 to $3.45.

    Apartment Investment and Management Company (AIV) tumbled over -6.75% at $4.7 in pre-market trading today following completion of separation of Apartment Income REIT Corp.

    Before the trading started on December 16, 2020, GeoVax Labs Inc. (GOVX) is down -7.86% to reach $3.4. It has been trading in a 52-week range of $2.30 to $60.00.

    Anchiano Therapeutics Ltd. (ANCN), a Biotechnology company, dropped about -7.99% at $2.65 in pre-market trading Wednesday after the company and and Chemomab Ltd. declared their entry into a definitive merger agreement.

    BEST Inc. (NYSE: BEST) shares are trading up 3.29% at $2.2 at the time of writing. Company’s 52-week ranged between $2.36 to $6.54. Analysts have a consensus price target of $3.50.

    Veru Inc. (VERU) stock moved down -7.5 percent to $8.63 in the pre-market trading. The company lately reported positive Phase 2 clinical trial results for Enobosarm.

    Northern Dynasty Minerals Ltd. (NAK) is up more than 3.67% at $0.325 in pre-market hours Wednesday December 16, 2020. The stock had dropped over -4.74% to $0.31 in the last trading session.

    Moderna Inc. (MRNA) stock plunged -3.33% to $142.32 in the pre-market trading. The company recently confirmed supply agreement with the Ministry of Health to supply Singapore with mRNA vaccine against COVID-19 (mRNA-1273). The most recent rating by Needham, on December 09, 2020, is a Hold.

    Before the trading started on December 16, 2020, Teligent Inc. (TLGT) is up 2.2% to reach $0.93. It has been trading in a 52-week range of $0.46 to $6.46.

    HEXO Corp. (HEXO), a Drug Manufacturers – Specialty & Generic company, rose about 2.75% at $1.12 in pre-market trading Wednesday. The firm recently revealed it first quarter fiscal 2021 financial results.

    Gevo Inc. (NASDAQ: GEVO) shares are trading up 4.74% at $1.99 at the time of writing. Company’s 52-week ranged between $0.46 to $2.91.

    Timber Pharmaceuticals Inc. (TMBR) stock moved down -0.97 percent to $1.02 in the pre-market trading after receiving notice of allowance from U.S. Patent and Trademark Office for Lead Asset TMB-001.

    Baidu Inc. (BIDU) is up more than 4.33% at $193.53 in pre-market hours Wednesday December 16, 2020. The stock had jumped over 13.83% to $185.50 in the last trading session.

    Aurora Cannabis Inc. (ACB) gained over 1.76% at $10.39 in pre-market trading Wednesday December 16, 2020 after provided a business update.

    Velodyne Lidar Inc. (VLDR) stock soared 3.91% to $20.2 in the pre-market trading after declaring a sales agreement for Alpha Prime sensors with May Mobility, a pioneer in autonomous vehicle (AV) technology. The most recent rating by Needham, on December 15, 2020, is a Buy.

    Before the trading started on December 16, 2020, Nikola Corporation (NKLA) is up 3.64% to reach $17.08. It has been trading in a 52-week range of $10.29 to $93.99.

    PG&E Corporation (NYSE: PCG) shares are trading up 2.87% at $12.55 at the time of writing after paying over $268 million in property taxes to 50 California counties. Company’s 52-week ranged between $6.25 to $18.34. Analysts have a consensus price target of $15.

    SELLAS Life Sciences Group Inc. (SLS) tumbled over -3.72% at $6.99 in pre-market trading today. The firm recently reported the pricing of $16.2 million registered direct offering.

    Nxt-ID Inc. (NASDAQ: NXTD) shares are trading down -1.66% at $0.4795 at the time of writing. Company’s 52-week ranged between $0.21 to $0.89.

    Qualigen Therapeutics Inc. (QLGN), a Biotechnology company, rose about 1.23% at $4.12 in pre-market trading Wednesday following its announcement of issuance of U.S. Patent for expanded applications of ALAN Anticancer Platform Technology.

    Concord Medical Services Holdings Limited (CCM) lost over -30.32% at $3.7 in pre-market trading Wednesday December 16, 2020.

    Aphria Inc. (APHA) grew over 11.45% at $9.05 in pre-market trading today following its declaration of definitive agreement with Tilray, Inc. (TLRY), to combine their businesses and create the world’s largest global cannabis company.

    Before the trading started on December 16, 2020, Hecla Mining Company (HL) is up 5.9% to reach $5.74. It has been trading in a 52-week range of $1.40 to $6.79.

    Twitter Inc. (TWTR), a Internet Content & Information company, rose about 3.1% at $54.46 in pre-market trading Wednesday after the declaration from the Amazon Web Services, Inc. (AWS), an Amazon.com, Inc. company (AMZN), that Twitter (TWTR) has selected AWS to provide global cloud infrastructure to deliver Twitter timelines.

    Torchlight Energy Resources Inc. (TRCH) stock plunged -4.63% to $0.5332 in the pre-market trading. The most recent rating by ROTH Capital, on March 13, 2020, is a Neutral.

    Arvinas Inc. (ARVN) is up more than 1.41% at $75.3 in pre-market hours Wednesday December 16, 2020 after reporting the pricing of an underwritten public offering of 5,714,286 shares of its common stock at a price of $70.00 per share, before underwriting discounts and commissions.

    Cinedigm Corp. (CIDM) stock plunged -0.54% to $0.84 in the pre-market trading. The most recent rating by The Benchmark Company, on July 07, 2020, is a Speculative buy.

    PDL BioPharma Inc. (PDLI) grew over 6.59% at $2.75 in pre-market trading today. The company recently reported that it has entered into a Capital Provision Agreement with Epps Investments LLC.

    vTv Therapeutics Inc. (VTVT) is down more than -31.99% at $2.02 in pre-market hours Wednesday December 16, 2020 after revealing that the Phase 2 Elevage study of azeliragon in people with mild Alzheimer’s disease and type 2 diabetes did not meet its primary objective of demonstrating an improvement in cognition as assessed by the 14-item Alzheimer’s Disease Assessment Scale – Cognitive Subscale (ADAS-cog14) relative to placebo.

  • What changed for these 31 stocks in Pre Market Session

    What changed for these 31 stocks in Pre Market Session

    Xenetic Biosciences Inc. (XBIO) stock plunged -15.46% to $2.68 in the pre-market trading following the company’s announcement of $6.0 million registered direct offering priced at-the-market under Nasdaq Rules. The most recent rating by Maxim Group, on January 08, 2020, is a Buy.
    Curis Inc. (CRIS), a Biotechnology company, dropped about -5.72% at $7.25 in pre-market trading Thursday after declaring the pricing of an underwritten public offering of 25,652,174 shares of its common stock at a public offering price of $5.75 per share for total gross proceeds of approximately $147.5 million.
    ZW Data Action Technologies Inc. (CNET) lost over -11.33% at $1.8 in pre-market trading Thursday December 10, 2020 after reporting the official opening of its first live streaming platform in Guangzhou, China.
    Genius Brands International Inc. (GNUS) is up more than 9.74% at $1.69 in pre-market hours Thursday December 10, 2020. The firm recently revealed that it will be presenting at the 13th Annual LD Micro investor conference on Tuesday, December 15th at 10:00 a.m. PST / 1:00 p.m. EST. The stock had dropped over -4.35% to $1.54 in the last trading session.
    Rocket Companies Inc. (RKT), a Mortgage Finance company, rose about 3.09% at $21.71 in pre-market trading Thursday following the release of Clear HOI platform from its subsidiary to mortgage lenders nationwide.
    Intec Pharma Ltd (NTEC) stock moved down -7.76 percent to $4.28 in the pre-market trading. Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma.
    Atossa Therapeutics Inc. (ATOS) gained over 2.31% at $0.8919 in pre-market trading Thursday December 10, 2020 after revealing cannabinoid research collaboration with GW Pharma.
    Nano Dimension Ltd. (NNDM) is up more than 2.25% at $6.82 in pre-market hours Thursday December 10, 2020 following the declaration from the company that it has closed the registered direct offering of 30,000,000 of the Company’s American Depositary Shares at a price of $6.00 per ADS. The stock had dropped over -6.06% to $6.67 in the last trading session.
    Before the trading started on December 10, 2020, Sorrento Therapeutics Inc. (SRNE) is down -2.44% to reach $8.01 following the FDA acceptance of its Investigational New Drug (IND) application for its Phase 1 clinical trials for intravenous (IV) STI-2020 (COVI-AMG). It has been trading in a 52-week range of $1.55 to $19.39.
    Genetic Technologies Limited (GENE) stock plunged -9.17% to $4.06 in the pre-market trading.
    Greenwich LifeSciences Inc. (GLSI) grew over 46.76% at $83.8 in pre-market trading today after reporting the publication of a poster for the GP2 Phase IIb clinical trial final efficacy analysis at the San Antonio Breast Cancer Symposium in a virtual format.
    Lipocine Inc. (LPCN), a Biotechnology company, dropped about -5.3% at $1.25 in pre-market trading Thursday after announcing that the U.S. Food and Drug Administration has granted tentative approval to TLANDO.
    SELLAS Life Sciences Group Inc. (SLS) stock moved up 51.8 percent to $9.7 in the pre-market trading. The biotechnology firm recently revealed exclusive license agreement with 3D Medicines for development and commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China.
    Francesca’s Holdings Corporation (NASDAQ: FRAN) shares are trading down -10.68% at $2.51 at the time of writing after receiving court approval of “First Day” motions to support ongoing operations. Company’s 52-week ranged between $1.70 to $19.91. Analysts have a consensus price target of $2.50.
    Oncternal Therapeutics Inc. (ONCT) tumbled over -27.78% at $4.55 in pre-market trading today after announcing that the firm increased its previously declared bought deal to $75.0 million.
    Gran Tierra Energy Inc. (GTE) is down more than -2.83% at $0.35 in pre-market hours Thursday December 10, 2020. The company recently declared a financial update and the Company’s 2021 capital budget and production guidance. The stock had dropped over -5.68% to $0.36 in the last trading session.
    Before the trading started on December 10, 2020, Fisker Inc. (FSR) is down -4.04% to reach $16.15. The firm recently confirmed that it has signed agreements with Cox Automotive U.K. (“Cox”) and Rivus Fleet Solutions for delivery, servicing, fleet management and reselling programs in the United Kingdom. It has been trading in a 52-week range of $8.70 to $23.63.
    Immutep Limited (IMMP) stock soared 89.35% to $4.09 in the pre-market trading after declaring that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China. The most recent rating by B. Riley FBR, on September 28, 2018, is a Buy.
    Remark Holdings Inc. (MARK), a Internet Content & Information company, rose about 3.09% at $1.67 in pre-market trading Thursday after reporting that Remark’s KanKan AI business successfully released its edge computing systems, the S and T Series Smart Boxes.
    Baidu Inc. (BIDU) gained over 2.42% at $155.26 in pre-market trading Thursday December 10, 2020. The firm recently released new intelligent vehicle solutions for automakers and several high-end intelligent driving products during the second Apollo Ecosystem Conference.
    Before the trading started on December 10, 2020, Editas Medicine Inc. (EDIT) is up 9.13% to reach $55.2 after reporting submission of IND application for EDIT-301 with the FDA. It has been trading in a 52-week range of $14.01 to $43.65.
    Artelo Biosciences Inc. (ARTL) stock plunged -2.47% to $0.66 in the pre-market trading. The healthcare firm recently declared that it has filed a composition of matter patent application directed to a new solid dosage formulation, including its method of use, with the UK Patent Office.
    AquaBounty Technologies Inc. (NASDAQ: AQB) shares are trading down -17.07% at $7.19 at the time of writing following the selection of Innovasea as the Recirculating Aquaculture Systems (“RAS”) technology provider for its planned 10,000 metric ton farm. Company’s 52-week ranged between $1.52 to $11.40. Analysts have a consensus price target of $5.
    Pluristem Therapeutics Inc. (PSTI) lost over -5.57% at $6.61 in pre-market trading Thursday December 10, 2020 after declaring DMC recommendation following interim analysis of its phase III CLI study.
    Before the trading started on December 10, 2020, Veru Inc. (VERU) is up 25.96% to reach $4.9 after reporting that it has exclusively licensed worldwide rights to enobosarm, a late-stage oral novel androgen receptor (AR) targeting agent for the treatment of endocrine resistant ER+ HER2- metastatic breast cancer. It has been trading in a 52-week range of $2.10 to $4.74.
    Uranium Energy Corp. (AMEX: UEC) shares are trading down -4.32% at $1.33 at the time of writing. Company’s 52-week ranged between $0.35 to $1.59. Analysts have a consensus price target of $1.50.
    Boxlight Corporation (BOXL), a Communication Equipment company, rose about 7.23% at $1.78 in pre-market trading Thursday. The firm recently confirmed that they are the recipients of three THE Journal’s Best New EdTech Product Awards.
    Regulus Therapeutics Inc. (RGLS) stock moved up 19.34 percent to $1.07 in the pre-market trading. The company lately announced closing of $19.4 million private placement of equity.
    Before the trading started on December 10, 2020, Sea Limited (SE) is down -3.3% to reach $196.0 after reporting that it proposes to offer 11,000,000 American Depositary Shares, each representing one Class A ordinary share of the Company, in an underwritten public offering. It has been trading in a 52-week range of $35.61 to $207.51.
    Barclays PLC (NYSE: BCS) shares are trading down -3.85% at $7.5 at the time of writing. The firm recently revealed the launch of BARX Book for Equities, a new single-dealer platform developed in partnership with Nasdaq (Nasdaq: NDAQ). Company’s 52-week ranged between $3.41 to $10.22.
    Qualigen Therapeutics Inc. (QLGN) stock moved up 13.85 percent to $4.44 in the pre-market trading. The company recently announced board member Amy Broidrick as EVP, Chief Strategy Officer and named Sidney Emery, Jr. to its board.

  • 15 Trending Stocks in Biotechnology Industry

    15 Trending Stocks in Biotechnology Industry

    The biggest movers of the 2020 are biotech stocks. Now, the COVID-19 pandemic has put brighter spotlight on the future of healthcare and specially biotech stocks have respond accordingly.

    Innovative biotech business have adopted the change and are competing to make what could become a life-saving treatment for millions in the form of a vaccine.

    Some of the biggest winners of this transformative mega-trend are discussed below.

    Genocea Biosciences Inc. (NASDAQ:GNCA) shares were trading up 24.44% at $4.48 at the time of writing on Friday.

    Genocea Biosciences Inc. (NASDAQ:GNCA) share price went from a low point around $1.10 to briefly over $3.86 in past 52 weeks, though shares have since pulled back to $4.48. GNCA market cap has remained high, hitting $99.50M at the time of writing, giving it price-to-sales ratio of more than 110.

    If we look at the recent analyst rating GNCA, SVB Leerink initiated coverage on GNCA shares with an Outperform.

    Arbutus Biopharma Corporation (ABUS) last closed at $4.96, in a 52-week range of $0.82 to $6.48. Analysts have a consensus price target of $5.00.

    Ocugen Inc. (OCGN) stock soar by 32.85% to $0.38.

    Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Shares headed falling, lower as much as -3.97%. The most recent rating by ROTH Capital, on April 18, 2019, is at a Buy.

    Capricor Therapeutics Inc. (NASDAQ:CAPR) rose 29.31% after gaining more than $1.75 on Friday.

    Ampio Pharmaceuticals Inc. (AMPE) last closed at $0.96, in a 52-week range of $0.26 to $0.97.

    iBio Inc. (IBIO) last closed at $5.50, in a 52-week range of $0.05 to $7.45.

    Novan Inc. (NOVN) stock soar by 6.06% to $0.86. The most recent rating by Piper Jaffray, on January 06, 2020, is at a Neutral.

    Onconova Therapeutics Inc. (NASDAQ:ONTX) Shares headed falling, lower as much as -2.63%. The most recent rating by H.C. Wainwright, on March 01, 2018, is at a Buy.

    Actinium Pharmaceuticals Inc. (AMEX:ATNM) rose 7.45% after gaining more than $0.03 on Friday.

    Sesen Bio Inc. (SESN) last closed at $0.99, in a 52-week range of $0.37 to $1.54.

    VistaGen Therapeutics Inc. (VTGN) stock drop by -4.39% to $0.76. The most recent rating by Maxim Group, on June 27, 2018, is at a Buy.

    Qualigen Therapeutics Inc. (NASDAQ:QLGN) Shares headed rising, higher as much as 11.22%.

    PolarityTE Inc. (NASDAQ:PTE) rose 10.56% after gaining more than $0.17 on Friday.

    Matinas BioPharma Holdings Inc. (MTNB) last closed at $0.96, in a 52-week range of $0.49 to $2.49.